(Q45752892)

15 December 2017

title

Maintenance of clinical remission in ANCA-associated vasculitis (English)

1 reference

15 December 2017

author

Raashid Ahmed Luqmani

series ordinal

1

1 reference

15 December 2017

language of work or name

English

0 references

publication date

13 November 2012

1 reference

15 December 2017

Nature Reviews Rheumatology

published in

1 reference

15 December 2017

volume

9

1 reference

15 December 2017

issue

2

1 reference

15 December 2017

page(s)

127-132

1 reference

15 December 2017

EULAR recommendations for the management of primary small and medium vessel vasculitis.

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.188

Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.188

Rituximab versus cyclophosphamide for ANCA-associated vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.188

Development of outcome measures for large-vessel vasculitis for use in clinical trials: opportunities, challenges, and research agenda

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.188

Long-term patient survival in ANCA-associated vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.188

Mortality in Wegener's granulomatosis: a bimodal pattern.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.188

EULAR points to consider in the development of classification and diagnostic criteria in systemic vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.188

Positive classic antineutrophil cytoplasmic antibody (C-ANCA) titer at switch to azathioprine therapy associated with relapse in proteinase 3-related vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.188

EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.188

Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.188

Etanercept plus standard therapy for Wegener's granulomatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.188

Deoxyspergualin in relapsing and refractory Wegener's granulomatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.188

Maintenance of remission with leflunomide in Wegener's granulomatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.188

BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.188

Azathioprine or methotrexate maintenance for ANCA-associated vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.188

Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.188

Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.188

Rituximab maintenance therapy for granulomatosis with polyangiitis and microscopic polyangiitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.188

Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.188

Co-trimoxazole and prevention of relapses of PR3-ANCA positive vasculitis with pulmonary involvement

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.188

Clinical findings and prognosis of polyarteritis nodosa and Churg-Strauss angiitis: a study in 165 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.188

Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis--a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.188

Risk factors associated with relapse in Japanese patients with microscopic polyangiitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.188

Glucocorticoids and relapse and infection rates in anti-neutrophil cytoplasmic antibody disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.188

The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.188

Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.188

A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.188

Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.188

Prospective study of TNFalpha blockade with adalimumab in ANCA-associated systemic vasculitis with renal involvement

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.188

Treatment of refractory Wegener's granulomatosis with antithymocyte globulin (ATG): an open study in 15 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.188

15-Deoxyspergualin in patients with refractory ANCA-associated systemic vasculitis: a six-month open-label trial to evaluate safety and efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.188

Intravenous immunoglobulins for relapses of systemic vasculitides associated with antineutrophil cytoplasmic autoantibodies: results of a multicenter, prospective, open-label study of twenty-two patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.188

Long-term follow-up of relapsing/refractory anti-neutrophil cytoplasm antibody associated vasculitis treated with the lymphocyte depleting antibody alemtuzumab (CAMPATH-1H).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.188

Wegener's granulomatosis: long-term follow-up of patients treated with pulse cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.188

2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.188

A staged approach to the treatment of Wegener's granulomatosis: induction of remission with glucocorticoids and daily cyclophosphamide switching to methotrexate for remission maintenance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.188

Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.188

Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.188

Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): ten-year experience at a single center

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.188

Long-term followup of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: analysis of four prospective trials including 278 patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.188

Treatment of polyarteritis nodosa and microscopic polyangiitis with poor prognosis factors: A prospective trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in sixty-five patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.188

Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.188

Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.188

Classical versus non-renal Wegener's granulomatosis

31 March 2020

1 reference

12 December 2020

Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis.

1 reference

12 December 2020

Development and validation of a disease extent index for Wegener's granulomatosis

1 reference

12 December 2020

Methotrexate plus leflunomide for the treatment of relapsingWegener's granulomatosis. A retrospective uncontrolled study

1 reference

12 December 2020

Treatment response and relapse in antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis

1 reference

12 December 2020

Intravenous immunoglobulin (IVIg) therapy in MPO-ANCA related polyangiitis with rapidly progressive glomerulonephritis in Japan

1 reference

12 December 2020

Baseline features and initial treatment as predictors of remission and relapse in Wegener's granulomatosis.

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRRHEUM.2012.188

1 reference

15 December 2017

Dimensions Publication ID

1025820368

0 references

1 reference

15 December 2017